Related Experiment Video
Updated: Mar 31, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
An update on renal artery denervation and its clinical impact on hypertensive disease
Aditya Bhat1, Ye Min Kuang1, Gary C H Gan1
1Department of Cardiology, Blacktown Mount Druitt Hospital, Blacktown Road, Blacktown, NSW 2148, Australia.
Insights
Renal artery denervation shows potential for resistant hypertension but its utility is debated following controversial trial results. This review evaluates the technology
Area of Science:
- Cardiology and Nephrology
- Interventional Cardiology
- Hypertension Management
Background:
- Hypertension is a major global health issue and primary risk factor for cardiovascular and cerebrovascular diseases.
- Resistant hypertension affects a significant patient subset, necessitating advanced treatment strategies.
- Catheter-based renal artery denervation (RAD) was proposed as a promising therapy for resistant hypertension.
Purpose of the Study:
- To critically evaluate the historical development and clinical utility of renal artery denervation technology.
- To assess the efficacy and safety of RAD based on a comprehensive review of existing literature and key clinical trials.
- To provide an in-depth appraisal of the current evidence, particularly in light of controversial trial outcomes.
Main Methods:
- Systematic review and critical appraisal of published literature on renal artery denervation.
- In-depth analysis of principal clinical trials, including large-scale randomized controlled studies like the Symplicity HTN-3 trial.
- Evaluation of safety and efficacy data from early trials and subsequent investigations.
Main Results:
- Early trials suggested favorable clinical efficacy and safety of RAD for resistant hypertension, with additional benefits observed in heart failure.
- The Symplicity HTN-3 trial introduced controversy regarding the efficacy and safety of RAD, challenging earlier findings.
- The utility of RAD in managing resistant hypertension remains a subject of ongoing debate within the medical community.
Conclusions:
- Renal artery denervation technology has evolved, but its definitive role in treating resistant hypertension requires further clarification.
- A balanced assessment of RAD's benefits and risks is crucial, considering the conflicting evidence from major trials.
- Continued research and rigorous evaluation are necessary to establish the long-term clinical value of renal artery denervation.
Abstract:
Hypertension is a globally prevalent condition, with a heavy clinical and economic burden. It is the predominant risk factor for premature cardiovascular and cerebrovascular disease, and is associated with a variety of clinical disorders including stroke, congestive cardiac failure, ischaemic heart disease, chronic renal failure, and peripheral arterial disease. A significant subset of hypertensive patients have resistant hypertensive disease. In this group of patients, catheter-based renal artery denervation has emerged as a potential therapy, with favourable clinical efficacy and safety in early trials. Additional benefits of this therapy are also being identified and include effects on left ventricular remodeling, cardiac performance, and symptom status in congestive cardiac failure. Utility of renal denervation for the management of resistant hypertension, however, has become controversial since the release of the Symplicity HTN-3 trial, the first large-scale blinded randomised study investigating the efficacy and safety of renal artery denervation. The aim of this paper is to evaluate the history, utility, and clinical efficacy of renal artery denervation technology, including an in-depth appraisal of the current literature and principal trials.
More Related Videos
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:29Hypertension II: Pathophysiology
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies